Anti-survivin T-cell receptor/anti-CD3 bispecific therapeutic ABBV-184

{
  "id": "MLC-T-ONC-011103",
  "term": "Anti-survivin T-cell receptor/anti-CD3 bispecific therapeutic ABBV-184",
  "field": "Oncology and biomedicine",
  "definition": "A T-cell redirecting bispecific therapeutic composed of a T-cell receptor (TCR) moiety specific for the tumor-associated antigen (TAA) survivin and a CD3 binding moiety, with potential immunostimulating and antineoplastic activities. Upon administration of anti-survivin TCR/anti-CD3 bispecific therapeutic ABBV-184, the TCR moiety of this agent targets and binds to survivin on tumor cells and the anti-CD3 moiety binds to CD3-expressing T lymphocytes. This selectively cross-links tumor cells and T lymphocytes and results in a CTL-mediated killing of survivin-expressing tumor cells. Survivin, a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development, is upregulated in a variety of human cancers while absent in most normal adult cells; its expression in tumors is associated with a more aggressive phenotype, decreased survival, and increased resistance to chemotherapy.",
  "synonyms": [
    "anti-survivin TCR/anti-CD3 bispecific therapeutic ABBV-184",
    "survivin TCR/CD3 bispecific therapeutic ABBV-184"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/anti-survivin-t-cell-receptor-anti-cd3-bispecific-therapeutic-abbv-184/"
}